CME Live Webinar

Digital decision-making in the management of Growth Disorders

16 October 2026
from 13.00 to 14.00 CEST

Register for FreeFinal Programme
scroll-down-icon
REGISTER FOR FREE
Final Programme

Click to watch the Pre-webinar interview

Overview

Rapid advances in connected health, mobile technology, artificial intelligence (AI), and gamification are making a difference in patient management [Tornincasa, 2022]. Artificial intelligence in medicine is transforming healthcare by personalising patient care based on  dataset  analyses [Dimitri, 2024]. AI can learn, reason, problem-solve, recognise patterns and understand language [Savage, 2025]. Digitalisation has improved patient access to information, which has facilitated monitoring, intervention and communications with healthcare professionals. Innovations for managing growth hormone in children and adolescents are some of the most broadly implemented digital health solutions in paediatrics [Tornincasa, 2022]. Although there are advantages and benefits to AI and digital solutions, awareness is needed regarding data privacy and, in particular, protecting children’s health data [Dimitri, 2024]. In addition, AI cannot create the patient-doctor relationship or assess the wider holistic determinants of care [Savage, 2025; Dimitri, 2024]. Height screening programmes are useful and cost-effective, providing an assessment of a child’s growth, and can help identify genetic disorders, diseases and other growth-related conditions [van Dommelen, 2025]. Automated growth tracking software integrated into Electronic Health Records systems can help healthcare professionals identify slow or accelerated growth during routine health checks [van Dommelen, 2025; Sankilampi, 2013]. 

Learning Objectives

At the end of the webinar, learners should be able to:

  • • Evaluate the role of AI and other technological advances in enhancing clinical care of patients with short stature
  • • Realise the value of height screening programmes
  • • Appreciate that digital technology can improve patient adherence to rhGH

Target Audience

Clinicians, particularly paediatricians, working in growth disorder management and those in general practice; some content of interest to specialist growth disorder nurses.

Language

English with simultaneous translation into Spanish and Korean

Continuing Medical Education

The Digital decision-making in the management of growth disorders – Virtual, Italy, 16/10/2026 – 16/10/2026 organized by MedEA Medical Education Academy has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

uems-eaccme-logo

The content of the Digital decision-making in the management of growth disorders has been certified by the CPD Certification Service as conforming to continuing professional development principles.

CME provider

MedEA Medical Education Academy

Director, Educational Programme Development: Flaminia Masprone

T 39 02 8295 8658

info@medeaacademy.com

Back to Main page

CME Live Webinar
Digital decision-making in the management of Growth Disorders

16 October 2026
from 13.00 to 14.00 CEST

Chair

Marco Cappa

Marco Cappa

Head of Research Unit
for Innovative Therapies for Endocrinopathies
Bambino Gesù Children’s Hospital
IRCCS
Rome, Italy
Biography

Faculty

Paul Dimitri

Paul Dimitri

Consultant in Paediatric Endocrinology at Sheffield Children’s NHS
Foundation Trust
Professor of Child Health Technology at the University of Sheffield
and Professor of Child Health at Sheffield Hallam University
Sheffield, UK
Biography
Paula van Dommelen

Paula van Dommelen

Scientist at The Netherlands Organization for Applied Scientific Research (TNO)
Department of Child Health
Leiden, The Netherlands
Biography

International Committee

Jeff Bolton

Jeff Bolton

Chair of Trustees
Child Growth Foundation
UK
Biography
Raúl Calzada León

Raúl Calzada León

President of the Latin-American Society of Pediatric Endocrinology (SLEP)
Head of the Endocrinology Service
National Institute of Pediatrics
Mexico City, Mexico
Biography
Muhammad Yazid Jalaludin

Muhammad Yazid Jalaludin

Professor of Paediatrics at the Faculty of Medicine
and Deputy Dean for Undergraduate Studies
Universiti Malaya, Malaysia
Senior Consultant Paediatrician and Senior Consultant Paediatric Endocrinologist at the
University Malaya Medical Centre and UM Specialist Centre
Malaya, Malaysia
Biography
Han-Wook Yoo

Han-Wook Yoo

Pediatric Endocrinologist
CHA Bundang Medical Center
CHA University School of Medicine and Emeritus Professor at Asan Medical Center Children’s Hospital
University of Ulsan College of Medicine
Republic of Korea
Biography

Partnerships

Child Growth Foundation (CGF)

Cyprus Endocrine Society (CES)

Korean Society of Pediatric Endocrinology (KSPE)

Malaysian Endocrine & Metabolic Society (MEMS)

Latin American Society for Pediatric Endocrinology (SLEP)

With the endorsement of the Società Italiana di Endocrinologia e Diabetologia Pediatrica (SIEDP)

Scientific Programme

Download

Agenda

AGENDA

FUNDING

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.

· Marco Cappa ·

Marco Cappa is Head of the Research Unit Innovative Therapies for Endocrinopathies at Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. He is Emeritus Professor of Paediatric Endocrinology and Paediatrics at La Sapienza University of Rome and Emeritus Professor of Paediatrics at the University of Tor Vergata, Rome, Italy. Professor Cappa’s specialties include endocrinology, paediatrics, and sports medicine. From 2011 to 2013, he served as President of the Italian Society of Paediatric Endocrinology and Diabetology (ISPED). In May 2025, he received the ESPE Outstanding Clinician Award. His main scientific areas of interest include neuroendocrinology and genetics, growth hormone testing, adrenoleukodystrophy, congenital adrenal hyperplasia, Prader–Willi syndrome, and rare thyroid disorders. He is a member of several professional organizations, including the Italian Society of Paediatric Endocrinology and Diabetes, the Italian Society of Endocrinology, the Italian Association of Clinical Endocrinologists (AME), The Endocrine Society, and the European Society for Paediatric Endocrinology. He serves as a reviewer for several international journals. Author and co-author of more than 480 publications (with 3,865 citations and an h-index of 53), he is also editor of 15 international books, author of more than 150 book chapters, and has conducted over 30 clinical trials in the field of paediatric endocrinology.

· Paul Dimitri ·

Paul Dimitri BSc, MBChB, FRCPCH, PhD is a Consultant in Paediatric Endocrinology at Sheffield Children’s NHS Foundation Trust, Professor of Child Health Technology at the University of Sheffield, and Professor of Child Health at Sheffield Hallam University. He has worked in paediatrics since 1998 and paediatric endocrinology since 2004, with clinical expertise in disorders of growth, puberty, and hormone regulation. He leads the Hypothalamic and Pituitary Tumour Service and co‑leads the Paediatric Late Effects Endocrinology service supporting childhood cancer survivors with endocrine complications. His research spans child health technology, endocrinology, and skeletal development, and he is widely published in these fields. Professor Dimitri is Director of the NIHR HealthTech Research Centre in Paediatrics and Child Health and Clinical Director of the national TITCH Network, driving innovation in child health technology. He previously directed the NIHR CYP MedTech Cooperative, the UK’s first paediatric MedTech Co‑operative, and served as NIHR National Children’s Specialty Lead from 2016–2024. He is Vice President for Science and Research at the Royal College of Paediatrics and Child Health, shaping national research policy. In 2025, he was awarded NIHR Senior Investigator status, recognising his leadership in applied child health research and his commitment to transforming healthcare for children and young people.

· Paula van Dommelen ·

Paula van Dommelen is a scientist at The Netherlands Organization for Applied Scientific Research (TNO). Her work focuses on developing technological innovations and data-driven solutions to improve child health worldwide. She develops innovative statistical methods, personalized child healthcare applications, decision support systems, youth healthcare guidelines, and implementation strategies, and conducts research on both mental and physical child health.

· Jeff Bolton ·

A BSc (Hons) and MBA graduate from Welsh universities, Jeff joined the pharmaceutical industry in 1990. Jeff first worked for Janssen-Cilag, where he performed a number of commercial and marketing management roles.

Jeff joined Pfizer in 2002 as Senior Brand Manager in the Endocrinology Team and transitioned into a European marketing role in 2006. Jeff became European Brand Director in 2010. Jeff left Pfizer in 2016 to start his own consultancy company, JRB Consultancy Services Ltd.

Jeff has been involved with growth conditions for over 20 years, and has won numerous awards, both national and international, for his role in developing campaigns and support information and materials for families affected by growth conditions. Jeff was the European lead for the development of the first growth prediction tool, iGRO, which was sponsored by Pfizer, and has since been rolled out in more than 25 countries.

Jeff has been a trustee of the Child Growth Foundation for over two years and became their Chair in 2022.

· Raúl Calzada León ·

Raúl Calzada León has been Chief of the Pediatric Endocrinology Service in the National Institute of Pediatrics, Mexico, since 1993. He was former President of the Mexican Society of Nutrition and Endocrinology and of the Mexican Society of Pediatric Endocrinology and is now the current President of the Latin-American Society of Pediatric Endocrinology. As well as clinical practice, Professor Calzada León is an active teacher and lecturer in endocrinology, pediatric endocrinology and clinical biochemistry at the National and Autonomous University of Mexico and the Medicine School at the National Polytechnic Institute of Mexico and advises nationally on Mexican health standards. He is a member of numerous national, regional and international societies for Endocrinology and Pediatrics. Professor Calzada León has published widely on many aspects of pediatric endocrinology, particularly on research into growth hormone treatment, congenital hypothyroidism, precocious puberty and early β-cell damage in pediatric patients with obesity and diabetes. He has been a member of the editorial board of Pediatric Endocrinology Review.

· Muhammad Yazid Jalaludin ·

Professor Dr Muhammad Yazid Jalaludin is The Deputy Dean (Undergraduate Studies) at the Faculty of Medicine, University Malaya. He is a Professor of Paediatrics at the Faculty of Medicine, Universiti Malaya and a practicing Senior Consultant Paediatrician and Senior Consultant Paediatric Endocrinologist at the University Malaya Medical Centre (UMMC). He completed his fellowship in Pediatric Endocrinology and Diabetes at Children’s Hospital of Philadelphia (CHOP), USA after obtaining his MBBS and Masters in Paediatrics, both from University Malaya. He is currently the Chairman of the Malaysian Paediatric Endocrinology and Diabetes Group (MPEDG), Vice President of the Malaysian Endocrine and Metabolic Society (MEMS 2022-2024), executive council member of the Malaysian Paediatric Association (MPA 2021-2023) and elected council member of Asia Pacific Paediatric Endocrine Society (APPES 2022-2024). Prof Jalaludin main research interest is in obesity and type 2 diabetes mellitus, growth (nutrition) and vitamin D in children. He holds many national and international research grants and acts as Scientific Advisor for many multi-centre international researches for type 2 diabetes and obesity in children. His work has been published in various academic journals including in the New England Journal of Medicine (NEJM).

· Han-Wook Yoo ·

Han-Wook Yoo received his M.D. from the College of Medicine, Seoul National University in 1979. He has completed his clinical training as an internship and residency in 1983 and clinical fellowship in Pediatrics at Seoul National University Children’s Hospital in 1986. He furthered his clinical and research training through a postdoctoral fellowship at Department of Pediatrics, Mount Sinai Medical Center, New York, U.S.A. from 1989 through 1992, and certified as clinical molecular geneticist by the American Board of Medical Genetics. In 1994, he joined the faculty of University of Ulsan College of Medicine, Asan Medical Center. In 2001, he became the Chief of the Department of Pediatrics. From 2009 through 2012, he has served as the president of Asan Medical Center Children’s Hospital in Seoul, Korea. After retirement from Asan Medical Center in Feb.-2022, he continued his academic career at CHA Bundang Medical Center, CHA University School of Medicine as a professor of Pediatrics and Center for Genomic Medicine. Professor Yoo has published more than 250 peer-reviewed articles. He has received several awards for his research and he is an active member of many international academic societies in the field of endocrinology and medical genetics. Professor Yoo’s main research interests are focused on the characterization of molecular & functional defects of endocrine genetic disorders.

Join our Newsletter!

Stay in the know with our CME updates

Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.